Synaptic signalling therapies for anti-acetylcholine receptor myasthenia gravis
This project will use a mouse model to test potential treatments for the autoimmune disease, anti-acetylcholine receptor myasthenia gravis.
Myasthenia gravis is a muscle weakness disease. Most cases are caused by autoimmune antibodies that bind to the acetylcholine receptors (AChR) in the postsynaptic membrane of the neuromuscular junction (NMJ). The current treatments for myasthenia gravis mainly involve immunosuppression. Additional treatment options are needed to better manage patient health. The aim of this project is to use the mouse active-immunization model of anti-AChR myasthenia gravis to test the benefit of new experimental interventions, including physical exercise and muscle specific kinase gene therapy. Mice will be carefully monitored for weight loss and muscle weakness. Impairment of NMJ function and structure will be assessed using electromyography and quantitative fluorescence microscopy. This project aims to establish new candidate treatments that can be tested for better health outcomes in myasthenia gravis patients.
Co-supervisor is Dr Stephen Reddel.
Want to find out more?
Contact Research Expert to find out more about participating in this opportunity.
Browse for other opportunities within the Camperdown - School of Medical Sciences - Bosch Institute .
The opportunity ID for this research opportunity is: 673
Other opportunities with Associate Professor William (Bill) Phillips